Home
Resources
Publications
BAY 87-2243, a Novel Inhibitor of Hypoxia-Induced Gene Activation, Improves Local Tumor Control After Fractionated Irradiation in a Schedule-Dependent Manner in Head and Neck Human Xenografts

BAY 87-2243, a Novel Inhibitor of Hypoxia-Induced Gene Activation, Improves Local Tumor Control After Fractionated Irradiation in a Schedule-Dependent Manner in Head and Neck Human Xenografts

Linda Helbig, Lydia Koi, Kerstin Brüchner, Kristin Gurtner, Holger Hess-Stumpp, Kerstin Unterschemmann, Michael Baumann, Daniel Zips, Ala Yaromina

Radiat Oncol. 2014 Sep 19;9:207.

PMID: 25234922

Abstract:

Background:
The transcription factor hypoxia-inducible factor-1 (HIF-1) pathway plays an important role in tumor response to cytotoxic treatments. We investigated the effects of a novel small molecule inhibitor of mitochondrial complex I and hypoxia-induced HIF-1 activity BAY-87-2243, on tumor microenvironment and response of human squamous cell carcinoma (hSCC) to clinically relevant fractionated radiotherapy (RT) with and without concomitant chemotherapy.
Methods:
When UT-SCC-5 hSCC xenografts in nude mice reached 6 mm in diameter BAY-87-2243 or carrier was administered before and/or during RT or radiochemotherapy with concomitant cisplatin (RCT). Local tumor control was evaluated 150 days after irradiation and the doses to control 50% of tumors (TCD50) were compared between treatment arms. Tumors were excised at different time points during BAY-87-2243 or carrier treatment for western blot and immunohistological investigations.
Results:
BAY-87-2243 markedly decreased nuclear HIF-1α expression and pimonidazole hypoxic fraction already after 3 days of drug treatment. BAY-87-2243 prior to RT significantly reduced TCD50 from 123 to 100 Gy (p=0.037). Additional BAY-87-2243 application during RT did not decrease TCD50. BAY-87-2243 before and during radiochemotherapy did not improve local tumor control.
Conclusions:
Pronounced reduction of tumor hypoxia by application of BAY-87-2243 prior to RT improved local tumor control. The results demonstrate that radiosensitizing effect importantly depends on treatment schedule. The data support further investigations of HIF-1 pathway inhibitors for radiotherapy and of predictive tests to select patients who will benefit from this combined treatment.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1227158851	BAY 87-2243		1227158-85-1	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: